Therefore, ITGA2–UEA is suggested to be a potential predictive biomarker for HNSCC radiotherapy response and tumor recurrence, but naturally, further studies including validation by functional analysis would be needed to confirm its role as a biomarker. This evidence concerns the gene ITGA2 and head and neck squamous cell carcinoma.